SCHEMBL29618376

SCHEMBL29618376

N#Cc1cnc2c(c1)OCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GRM5 P41594 3/20 0.37
HTT P42858 2/20 0.37
MAOB P27338 1/20 0.35
EGFR P00533 1/20 0.34
PKM P14618 2/20 0.33
PKLR P30613 1/20 0.33
GSK3B P49841 3/20 0.32
MAPT P10636 2/20 0.32
VNN1 O95497 1/20 0.32
HPGDS O60760 2/20 0.31
GSK3A P49840 2/20 0.31
AURKA O14965 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14376061 0.72 GRM5 (0.67) ALDH1A1GAAGRM5HTTMAPT
SCHEMBL846335 0.72 MAP3K14 (0.35) LMNAKDM4EALDH1A1GAAL3MBTL1
SCHEMBL26119245 0.72 ACHE (0.31)
SCHEMBL31168610 0.72 PKM (0.34) ALDH1A1GAAMAOBPKMMAPT
SCHEMBL827778 0.72 PKM (0.34) ALDH1A1GAAMAOBPKMMAPT
SCHEMBL13459980 0.72 MAPT (0.36) KDM4EGAAMAPTRAB9ASMN1; SMN2
SCHEMBL19023235 0.72 MAOA (0.41) MAOB
SCHEMBL31168577 0.72 NPC1 (0.32) GRM5MAOBMAPTNPC1RAB9A
SCHEMBL31168664 0.72 IDO1 (0.34) LMNAL3MBTL1MAOBPKMMAPT
SCHEMBL619585 0.72 HTT (0.37) LMNAL3MBTL1HTTMAOBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022121805-A1 FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF 成都康弘药业集团股份有限公司 2022-06-16 WO disclosed
CN-114591293-A Fused ring compound as Nav1.8 inhibitor and application thereof 成都康弘药业集团股份有限公司 2022-06-07 CN disclosed